Should I Buy Zodus (ZTS)? Finance YouTuber Analysis

The analyst is avoiding Zoetis, despite its historically low P/E ratio of 12, because the company is experiencing weakening demand, increased competition, and a significant deceleration in revenue and earnings growth. He believes the current valuation is fair for a low single-digit growth company and prefers higher-quality businesses.

“I really just think that there are higher quality stocks in the market, and this one seems like it needs something to change.”

The YouTuber explains Michael Burry's 'fat pitch' assessment of Zoetis, an animal medicine company, despite ongoing legal issues. Burry believes the long-term business remains strong and undervalued, seeing past short-term noise to a clear opportunity.

“He looked at all that noise and said, 'The long-term business is still good. I'm buying.'”

The YouTuber briefly mentions Zoetis as a stock Michael Burry likes, noting that its numbers show stability or growth. While he doesn't delve into deep analysis due to his unfamiliarity with pharmaceutical stocks, he implies it's a good bet based on its fundamentals.

“If we look at the numbers, everything is stable or growing. So, you have to see how it fits you. Burry likes it.”

The YouTuber suggests buying Zoetis, noting its current P/E ratio is below 20, a significant drop from its previous high valuation of over 50. Despite recent underperformance, it remains a quality stock in animal health, making it an attractive buy at its current, more favorable valuation.

“Zötis ist vom Bewertungsniveau kann man ja man kann alles miteinander vergleichen. Machen wir jetzt mal hier Iron Mountain noch mit rein. V Bewertungsniveau natürlich deutlich günstiger.”

The analyst recommends Zoetis due to its market dominance in animal health, consistent revenue growth significantly above the industry average, and strong profitability with a 38% earnings margin. The company's competitive advantage and low threat of new entrants position it well for continued growth.

“what Drew me to zus though is its market dominance in the segment”

The analyst believes Zoetis is a high-quality company with strong revenue growth, expanding margins, and healthy free cash flow. However, he finds the current valuation too high, trading at a premium that limits potential long-term returns. He would consider buying if the stock price drops to $120, which would offer a more attractive return profile.

“I think the stock could come down in price so I'm gonna continue to watch it if it does come down in price uh you know I'd be a buyer at 120 that's kind of where I would start buying it if I'm interested in the stock right now with the current forecast it's a six percent the stock price comes down I expect that return would go up.”